These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [Cyclooxygenases in the spinal cord and the relationship with pain]. Li SQ; Li WB Sheng Li Ke Xue Jin Zhan; 2003 Oct; 34(4):359-60. PubMed ID: 14992024 [No Abstract] [Full Text] [Related]
4. [Colorectal cancer and inhibition of cyclooxygenase-2]. Geissler M; Mohr L; Blum HE Dtsch Med Wochenschr; 2002 Jun; 127(23):1256-8. PubMed ID: 12053285 [No Abstract] [Full Text] [Related]
5. Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance. Weber AA; Zimmermann KC; Meyer-Kirchrath J; Schrör K Lancet; 1999 Mar; 353(9156):900. PubMed ID: 10093990 [No Abstract] [Full Text] [Related]
6. [Therapy with preferential and specific COX-2 inhibitors]. Stichtenoth DO; Frölich JC Internist (Berl); 2001 Mar; 42(3):421-6. PubMed ID: 11277028 [No Abstract] [Full Text] [Related]
7. Non-steroidal anti-inflammatory and cyclooxygenase-2-selective inhibitors in clinical cancer prevention trials. Hawk ET; Viner JL; Umar A Prog Exp Tumor Res; 2003; 37():210-42. PubMed ID: 12795057 [No Abstract] [Full Text] [Related]
8. Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs. Patrono C; Patrignani P; García Rodríguez LA J Clin Invest; 2001 Jul; 108(1):7-13. PubMed ID: 11435450 [No Abstract] [Full Text] [Related]
9. Aspirin use and potential mechanisms for colorectal cancer prevention. Williams CS; Smalley W; DuBois RN J Clin Invest; 1997 Sep; 100(6):1325-9. PubMed ID: 9294096 [No Abstract] [Full Text] [Related]
10. Pharmacology and clinical action of COX-2 selective NSAIDs. Bovill JG Adv Exp Med Biol; 2003; 523():201-14. PubMed ID: 15088852 [No Abstract] [Full Text] [Related]
13. The promise of coxibs: how far have we progressed? Schumacher HR J Pain Symptom Manage; 2002 Apr; 23(4 Suppl):S1-4. PubMed ID: 11992742 [No Abstract] [Full Text] [Related]
14. [Selective cyclooxygenase-2 (COX-2) inhibitors: importance and limitations]. Pairet M; Netter P Therapie; 1999; 54(4):433-45. PubMed ID: 10667110 [TBL] [Abstract][Full Text] [Related]
15. COX-1 and COX-2 inhibition: current status and future perspective. Greyn J; Lauwers MH; Vanlersberghe C; Camu F Acta Anaesthesiol Belg; 1998; 49(3):175-83. PubMed ID: 9844704 [No Abstract] [Full Text] [Related]
17. Cyclooxygenase-2 inhibitors in cancer prevention and treatment. Masferrer JL Adv Exp Med Biol; 2003; 532():209-13. PubMed ID: 12908559 [No Abstract] [Full Text] [Related]
18. Cyclooxygenase inhibition in cancer prevention and treatment. Anderson WF; Umar A; Hawk ET Expert Opin Pharmacother; 2003 Dec; 4(12):2193-204. PubMed ID: 14640918 [TBL] [Abstract][Full Text] [Related]
19. Selective cyclooxygenase-2 inhibitors as potential therapeutic agents for inflammatory diseases. Chan CC; Rodger IW Adv Exp Med Biol; 1997; 407():157-61. PubMed ID: 9321947 [No Abstract] [Full Text] [Related]